Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE: Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Results from a phase Ib and II study showed the feasibility of combining romidepsin with CHOP (Ro-CHOP). METHODS: This study is a randomized phase III study of Ro-CHOP versus CHOP in adult patients with previously untreated PTCL. All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m 2, was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. The primary end point was progression-free survival (PFS) according to International Working Group 1999 criteria. RESULTS: Between January 2013 and December 2017, 421 patients were enrolled (Ro-CHOP, n = 211; CHOP, n = 210). The median PFS for Ro-CHOP versus CHOP was 12.0 months (95% CI, 9.0 to 25.8) versus 10.2 months (95% CI, 7.4 to 13.2) with a hazard ratio of 0.81 ( P = .096). In the Ro-CHOP versus CHOP arms, the median overall survival was 51.8 versus 42.9 months and the objective response rate was 63% versus 60% with complete response plus unconfirmed complete response rates of 41% versus 37% ( P > .1 in all comparisons), respectively. Grade 3 or 4 treatment-emergent adverse events occurring in ≥ 30% of patients in the Ro-CHOP arm included thrombocytopenia (50% v 10% in the Ro-CHOP v CHOP arms, respectively), neutropenia (49% v 33%), anemia (47% v 17%), and leukopenia (32% v 20%). CONCLUSION: The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,108 · cited 2×
“Corresponding 5-year OS rates were 32%, 32%, and 49%, respectively.(1) In the study published by the German group in patients treated with standard or intensified CHOP with or without etoposide, the 3-year EFS and OS were 41% and 54% for PTCL-NOS, 50% and 67% for AITL, and 46% and 62% for ALKnegative ALCL.”
BackgroundHorwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739 · cited 2×
“Over the past two decades, the only novel agent approved in the first-line setting has been brentuximab vedotin (BV) for CD301 PTCL in the United States and Japan and for ALCL in Europe, in association with cyclophosphamide, doxorubicin, and prednisone (CHP) on the basis of the results of the ECHELON-2 trial.(9) Subgr…”
BackgroundMethodSelf-citationCoiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4223 · Cited by 680 · cited 1×
“As a single agent in relapsed or refractory (R/R) PTCL, romidepsin was associated with 25% response rate including 15% of complete response (CR) or unconfirmed complete response (CRu).(10) Results from a phase Ib and II study showed the feasibility of combining romidepsin with cyclophosphamide, doxorubicin, vincristin…”
BackgroundSelf-citationWhittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664 · cited 1×
“Cardiac toxicity was monitored as an adverse event of special interest because of previously reported early cardiac events or T-wave abnormalities with romidepsin.(11,13) Importantly, no difference was observed between the two treatment arms despite more frequent metabolism disorders and especially grade $ 3 hypokalem…”
BackgroundUp-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594 · cited 1×
“A large prospective trial from the Nordic Lymphoma Group has reported long PFS with a median of more than 30 months after six cycles of CHOEP (CHOP plus etoposide) and ASCT following the conditioning regimen.(17) However, the lack of random assignment against a control arm without ASCT consolidation precluded drawing…”
BackgroundLaurent, C., Baron, M., Amara, N., Haioun, C., Dandoit, M., Maynadié, M., Parrens, M., Vergier, B., Copie-Bergman, C., Fabiani, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2083 · Cited by 230
Self-citationFalchi, L., Ma, H., Klein, S., Lue, J. K., Montanari, F., Marchi, E., Deng, C., Kim, H. A., Rada, A. M., Jacob, A. T., et al. (2020) · Blood · doi:10.1182/blood.2020009004 · Cited by 209
Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas‐Virelizier, E., Toussaint, E., Lancesseur, C., Bras, F. L., Willems, E., Tchernonog, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx787 · Cited by 143
Self-citationGhione, P., Faruque, P. R., Mehta–Shah, N., Seshan, V., Özkaya, N., Bhaskar, S., Yeung, J., Spinner, M. A., Lunning, M. A., Inghirami, G. G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002396 · Cited by 108 · cited 1×
“Although statistical considerations preclude any firm conclusion, this is in line with previous reports showing prolonged response duration in patients with R/R AITL treated with romidepsin and a recent retrospective study finding a benefit of histone deacetylase inhibitors in PTCL exhibiting a TFH phenotype.(14,15)”
ResultSelf-citationfor the ACT-2 study investigators, Wulf, G. G., Altmann, B., Ziepert, M., d’Amore, F., Held, G., Greil, R., Tournilhac, O., Relander, T., Viardot, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0838-5 · Cited by 99 · cited 2×
“Alemtuzumab in association with CHOP did not show any superiority in young nor in elderly patients.(7,8) The addition of BV to CHP was associated with a prolonged PFS and OS in PTCL with more than 10% CD301 tumoral cells by immunohistochemistry.”
MethodSelf-citationPro, B., Horwitz, S. M., Prince, H. M., Foss, F. M., Sokol, L., Greenwood, M. J., Caballero, D. M., Morschhauser, F., Wilhelm, M., Iyer, S. P., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2320 · Cited by 63 · cited 1×
“Although statistical considerations preclude any firm conclusion, this is in line with previous reports showing prolonged response duration in patients with R/R AITL treated with romidepsin and a recent retrospective study finding a benefit of histone deacetylase inhibitors in PTCL exhibiting a TFH phenotype.(14,15)”
ResultSelf-citation
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Li, J., Qiu, K., Rao, Y., Cheng, D., Song, Y., Shao, X., Jiang, C., Shu, T., Xu, W., Zhao, Y., et al. (2026) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-026-10663-5
Self-citation
Metadata
- Authors
- Bachy, E., Camus, V., Thieblemont, C., Sibon, D., Casasnovas, R.-O., Ysebaert, L., Damaj, G., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., André, M., García-Sancho, A. M., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Re, A., Gaulard, P., Delfau-Larue, M.-H., de Leval, L., Meignan, M., Li, J., Morschhauser, F., & Delarue, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-01-20
- Volume
- 40
- Issue
- 3
- Pages
- 242-251
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3217609143
- Cited by
- 197
- References
- 13
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.